EYPT (EyePoint Pharmaceuticals) Growth Rank : 2 (As of Apr. 17, 2025)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Growth Rank?

EyePoint Pharmaceuticals has the Growth Rank of 2.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Competitive Comparison of EyePoint Pharmaceuticals's Growth Rank

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's Growth Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Growth Rank distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Growth Rank falls into.

Save Embed

;

Save Embed

;

EyePoint Pharmaceuticals Growth Rank Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

PV3B:Germany PV3B:Germany

Address

480 Pleasant Street, Suite A-210, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Executives

Goran Ando	director
Wendy F Dicicco	director
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Nancy Lurker	director, officer: President and CEO	PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
David R Guyer	director	ONE PENN PLAZA, 19TH FLOOR, NEW YORK NY 10119
David Scott Jones	officer: SVP & Chief Commercial Officer	C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
Dario A. Paggiarino	officer: Chief Medical Officer	4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Ye Liu	director	ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Michael Craig Pine	officer: Chief Corp Dev.&Strat. Officer	C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p.	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Anthony P Adamis	director	3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension	10 percent owner	56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston	officer: Chief Financial Officer	124 CHATHAM STREET, CHATHAM NJ 07928
John B. Landis	director	1700 KENT AVENUE, WEST LAFAYETTE IN 46906